thalidomide has been researched along with Angiodysplasia in 40 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Angiodysplasia: Acquired degenerative dilation or expansion (ectasia) of normal BLOOD VESSELS, often associated with aging. They are isolated, tortuous, thin-walled vessels and sources of bleeding. They occur most often in mucosal capillaries of the GASTROINTESTINAL TRACT leading to GASTROINTESTINAL HEMORRHAGE and ANEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 9.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "to assess the efficacy of thalidomide in the treatment of relapsed or refractory bleeding secondary to gastrointestinal angiodysplasia." | 9.16 | Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. ( Bellido, F; Garrido, A; León, R; López, J; Márquez, JL; Sayago, M, 2012) |
| "This pilot study assesses the efficacy, safety, and side-effect of thalidomide in the treatment of patients with chronic gastrointestinal bleeding from angiodysplasias." | 9.14 | Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. ( Cirocco, M; Kamalaporn, P; Kandel, G; Kortan, P; Marcon, N; May, G; Saravanan, R, 2009) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 8.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 8.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 7.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| "To investigate the inhibitory effect of thalidomide on angiodysplasia." | 7.75 | [The mechanisms of thalidomide in treatment of angiodysplasia due to hypoxia]. ( Chen, HM; Fang, JY; Ge, ZZ; Liu, WZ; Lu, H; Xiao, SD; Xu, CH, 2009) |
| "Thalidomide seems to inhibit growth of intestinal angiodysplasias and may be useful for treatment of patients with bleeding related to angiodysplasias." | 7.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 5.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "Lenalidomide is a thalidomide analog with anti-angiogenic properties." | 5.48 | Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. ( Bull-Henry, K; Kessler, CM; Khatri, NV; Kohli, DR; Patel, B; Solomon, SS, 2018) |
| "Angiodysplasias are one of the reasons of gastrointestinal bleeding, whose origin is usually due to vascular malformations." | 5.43 | Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias. ( Cardaba Garcia, E; Hernando Verdugo, M; Izquierdo Navarro, Mdel C; Sanchez Sanchez, MT, 2016) |
| "Thalidomide can suppress VEGF, either induced by HIF-1α or bFGF." | 5.38 | Role of vascular endothelial growth factor in angiodysplasia: an interventional study with thalidomide. ( Chen, H; Fang, J; Gao, Y; Ge, Z; Liu, W; Tan, H; Xiao, S; Xu, C, 2012) |
| "Angiodysplasias are a major cause of lower gastrointestinal bleeding in patients over the age of 60 years." | 5.35 | A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. ( Dabak, V; Kamboj, G; Kuriakose, P; Shurafa, M, 2008) |
| "Angiodysplasias were detected and subsequently coagulated in the course of repeated gastroscopies and colonoscopies." | 5.33 | [Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias]. ( de Koning, DB; Drenth, JP; Friederich, P; Nagengast, FM, 2006) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 5.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| "to assess the efficacy of thalidomide in the treatment of relapsed or refractory bleeding secondary to gastrointestinal angiodysplasia." | 5.16 | Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. ( Bellido, F; Garrido, A; León, R; López, J; Márquez, JL; Sayago, M, 2012) |
| "This pilot study assesses the efficacy, safety, and side-effect of thalidomide in the treatment of patients with chronic gastrointestinal bleeding from angiodysplasias." | 5.14 | Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. ( Cirocco, M; Kamalaporn, P; Kandel, G; Kortan, P; Marcon, N; May, G; Saravanan, R, 2009) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 4.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| " Thalidomide has emerged as a promising medical strategy in angiodysplasia-related bleeding." | 4.91 | Thalidomide in angiodysplasia-related bleeding. ( Boey, JP; Hahn, U; McRae, SJ; Sagheer, S, 2015) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 3.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| "Thalidomide seems to inhibit growth of intestinal angiodysplasias and may be useful for treatment of patients with bleeding related to angiodysplasias." | 3.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| "Angiodysplasia is a rare, but important, cause of both overt and occult GI bleeding especially in the older patients." | 2.50 | Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. ( Al-Araji, SA; Ragunath, K; Sami, SS, 2014) |
| "Lenalidomide is a thalidomide analog with anti-angiogenic properties." | 1.48 | Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. ( Bull-Henry, K; Kessler, CM; Khatri, NV; Kohli, DR; Patel, B; Solomon, SS, 2018) |
| "Angiodysplasias are one of the reasons of gastrointestinal bleeding, whose origin is usually due to vascular malformations." | 1.43 | Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias. ( Cardaba Garcia, E; Hernando Verdugo, M; Izquierdo Navarro, Mdel C; Sanchez Sanchez, MT, 2016) |
| "Angiodysplasias are a major cause of lower gastrointestinal bleeding in patients over the age of 60 years." | 1.35 | A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. ( Dabak, V; Kamboj, G; Kuriakose, P; Shurafa, M, 2008) |
| "Angiodysplasias were detected and subsequently coagulated in the course of repeated gastroscopies and colonoscopies." | 1.33 | [Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias]. ( de Koning, DB; Drenth, JP; Friederich, P; Nagengast, FM, 2006) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 1.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (50.00) | 29.6817 |
| 2010's | 18 (45.00) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H | 3 |
| Wu, S | 1 |
| Tang, M | 1 |
| Zhao, R | 1 |
| Zhang, Q | 1 |
| Dai, Z | 1 |
| Gao, Y | 2 |
| Yang, S | 1 |
| Li, Z | 1 |
| Du, Y | 1 |
| Yang, A | 1 |
| Zhong, L | 1 |
| Lu, L | 1 |
| Xu, L | 1 |
| Shen, X | 1 |
| Liu, S | 1 |
| Zhong, J | 1 |
| Li, X | 1 |
| Lu, H | 2 |
| Xiong, H | 1 |
| Shen, Y | 1 |
| Gong, S | 1 |
| Xue, H | 1 |
| Ge, Z | 2 |
| Paciullo, F | 1 |
| Fierro, T | 1 |
| Calcinaro, F | 1 |
| Zucca Giucca, G | 1 |
| Gresele, P | 1 |
| Bury, L | 1 |
| Becq, A | 1 |
| Rahmi, G | 1 |
| Perrod, G | 1 |
| Cellier, C | 1 |
| Khatri, NV | 1 |
| Patel, B | 1 |
| Kohli, DR | 1 |
| Solomon, SS | 1 |
| Bull-Henry, K | 1 |
| Kessler, CM | 1 |
| Nardone, G | 1 |
| Compare, D | 1 |
| Martino, A | 1 |
| Rocco, A | 1 |
| Hude, I | 1 |
| Batinić, J | 1 |
| Kinda, SB | 1 |
| Pulanić, D | 1 |
| Wang, XY | 1 |
| Chen, Y | 1 |
| Du, Q | 1 |
| Sami, SS | 1 |
| Al-Araji, SA | 1 |
| Ragunath, K | 1 |
| Draper, K | 1 |
| Kale, P | 1 |
| Martin, B | 1 |
| Kelly Cordero, R | 1 |
| Ha, R | 1 |
| Banerjee, D | 1 |
| Engelen, ET | 1 |
| van Galen, KP | 1 |
| Schutgens, RE | 1 |
| Boey, JP | 1 |
| Hahn, U | 1 |
| Sagheer, S | 1 |
| McRae, SJ | 1 |
| Bond, A | 1 |
| Ahmed, W | 1 |
| Izquierdo Navarro, Mdel C | 1 |
| Hernando Verdugo, M | 1 |
| Cardaba Garcia, E | 1 |
| Sanchez Sanchez, MT | 1 |
| Serralta de Colsa, D | 1 |
| Arjona Medina, I | 1 |
| García Marín, A | 1 |
| Sanz Sánchez, M | 1 |
| Turégano Fuentes, F | 1 |
| Alberto, SF | 1 |
| Felix, J | 1 |
| de Deus, J | 1 |
| Mimidis, K | 1 |
| Kaliontzidou, M | 1 |
| Tzimas, T | 1 |
| Papadopoulos, V | 1 |
| Bowcock, SJ | 1 |
| Patrick, HE | 1 |
| Fernández Salazar, LI | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Galante, I | 1 |
| Aller de la Fuente, R | 1 |
| González Hernández, JM | 1 |
| Jimenez-Saenz, M | 1 |
| Romero-Vazquez, J | 1 |
| Caunedo-Alvarez, A | 1 |
| Maldonado-Perez, B | 1 |
| Gutierrez, JM | 1 |
| Chen, HM | 2 |
| Ge, ZZ | 2 |
| Liu, WZ | 1 |
| Xu, CH | 1 |
| Fang, JY | 1 |
| Xiao, SD | 1 |
| Nomikou, E | 1 |
| Tsevrenis, V | 1 |
| Gafou, A | 1 |
| Bellia, M | 1 |
| Theodossiades, G | 1 |
| Kamalaporn, P | 1 |
| Saravanan, R | 1 |
| Cirocco, M | 1 |
| May, G | 1 |
| Kortan, P | 1 |
| Kandel, G | 1 |
| Marcon, N | 1 |
| Bauditz, J | 3 |
| Almadi, M | 1 |
| Ghali, PM | 1 |
| Constantin, A | 1 |
| Galipeau, J | 1 |
| Szilagyi, A | 1 |
| Bélard, E | 1 |
| Foss, CH | 1 |
| Christensen, LA | 1 |
| Schmidt, P | 1 |
| Nøjgaard, C | 1 |
| Molina-Infante, J | 1 |
| Perez-Gallardo, B | 1 |
| Vega, J | 1 |
| Goecke, H | 1 |
| Rodríguez, Mde L | 1 |
| Vergara, MT | 1 |
| Tan, H | 1 |
| Xu, C | 1 |
| Fang, J | 1 |
| Liu, W | 1 |
| Xiao, S | 1 |
| Garrido, A | 1 |
| Sayago, M | 1 |
| López, J | 1 |
| León, R | 1 |
| Bellido, F | 1 |
| Márquez, JL | 1 |
| Alam, MA | 1 |
| Sami, S | 1 |
| Babu, S | 1 |
| Tan, HH | 1 |
| Gao, YJ | 1 |
| Shurafa, M | 2 |
| Kamboj, G | 2 |
| Hirri, HM | 1 |
| Green, PJ | 1 |
| Lindsay, J | 1 |
| Kirkham, SE | 1 |
| Lindley, KJ | 1 |
| Elawad, MA | 1 |
| Blanshard, C | 1 |
| Shah, N | 1 |
| de Koning, DB | 1 |
| Drenth, JP | 1 |
| Friederich, P | 1 |
| Nagengast, FM | 1 |
| Lochs, H | 2 |
| Voderholzer, W | 1 |
| Powell, RJ | 1 |
| Heidt, J | 1 |
| Langers, AM | 1 |
| van der Meer, FJ | 1 |
| Brouwer, RE | 1 |
| Dabak, V | 1 |
| Kuriakose, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)[NCT05570448] | 36 participants (Anticipated) | Interventional | 2022-02-15 | Recruiting | |||
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding[NCT04680195] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-12-14 | Not yet recruiting | ||
| A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Efficacy of Thalidomide for Refractory Small Intestinal Bleeding From Vascular Malformation[NCT02707484] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study[NCT00964496] | Phase 2 | 55 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study[NCT02301949] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn | ||
| Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure[NCT02622906] | Phase 2 | 24 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment. (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 13 |
| Iron-controlled Group | 0 |
The change from baseline in bleeding duration at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | days (Mean) |
|---|---|
| Thalidomide Group | 5.2 |
| Iron-controlled Group | 0.8 |
The Change from baseline in bleeding episodes at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | bleeding episodes (Mean) |
|---|---|
| Thalidomide Group | -9.36 |
| Iron-controlled Group | 1.41 |
The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | g/L (Mean) |
|---|---|
| Thalidomide Group | 3.06 |
| Iron-controlled Group | -0.01 |
Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | milliliter (Mean) |
|---|---|
| Thalidomide Group | -1585.71 |
| Iron-controlled Group | -28.57 |
Numbers of participants dependent on blood transfusions (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 3 |
| Iron-controlled Group | 13 |
The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 20 |
| Iron-controlled Group | 1 |
8 reviews available for thalidomide and Angiodysplasia
| Article | Year |
|---|---|
Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Argon Plasma Coagulation; Electrocoagulation; Embolization, | 2017 |
Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE).
Topics: Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Italy; Practice Guidelines as Topic; Progestero | 2018 |
Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management.
Topics: Angiodysplasia; Electrocoagulation; Gastrointestinal Hemorrhage; Humans; Octreotide; Thalidomide | 2014 |
Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.
Topics: Aged; Angiodysplasia; Databases, Factual; Epistaxis; Female; Gastrointestinal Hemorrhage; Humans; Me | 2015 |
Thalidomide in angiodysplasia-related bleeding.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Human | 2015 |
[Angiogenesis inhibitors for treatment of angiodysplasia-related gastrointestinal bleeding].
Topics: Angiodysplasia; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2009 |
Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Angiography; Animals; Antifibrinol | 2009 |
Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Thalidomide; Vascular | 2007 |
3 trials available for thalidomide and Angiodysplasia
| Article | Year |
|---|---|
Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.
Topics: Administration, Oral; Angiodysplasia; China; Double-Blind Method; Gastrointestinal Hemorrhage; Hemat | 2023 |
Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Blood Transfusion; Chronic Disease | 2009 |
Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhag | 2012 |
29 other studies available for thalidomide and Angiodysplasia
| Article | Year |
|---|---|
Long-term treatment with thalidomide for severe recurrent hemorrhage from intestinal angiodysplasia in Glanzmann Thrombasthenia.
Topics: Aged; Angiodysplasia; Female; Humans; Thalidomide; Thrombasthenia | 2021 |
Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Retrospective Stu | 2018 |
Successful Treatment of Recurrent Gastrointestinal Bleeding Due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide: Two Birds with One Stone
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Intestine, Small | 2018 |
Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia.
Topics: Aged; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Stomach Diseases; Telan | 2013 |
Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol.
Topics: Adult; Aged; Angiodysplasia; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Gast | 2015 |
Thalidomide for the treatment of angiodysplasia in a patient with acute upper gastrointestinal haemorrhage.
Topics: Acute Disease; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Endoscopy; Female; Gastro | 2016 |
Therapeutic failure with thalidomide in patients with recurrent intestinal bleeding due to angiodysplasias.
Topics: Aged; Anemia; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Immunosuppressive Agents; Male; M | 2016 |
[Invalidating and recurrent gastrointestinal bleeding caused by intestinal angiodysplasia: treatment with thalidomide].
Topics: Aged; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Severity of Illness Ind | 2008 |
Thalidomide for the treatment of severe intestinal bleeding.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Gastrointestinal Hemorrhage | 2008 |
Thalidomide for treatment of bleeding angiodysplasias during hemodialysis.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Kidney Failure, | 2008 |
Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Chronic Disease; Female; Gastrointestinal Hemorrhage; | 2009 |
[Efficacy of thalidomide in digestive bleeding caused by angiodysplasias].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Cardiovascular Diseases; Cerebellar Neoplasms; Cerebe | 2009 |
Beneficial effects and reversion of vascular lesions by thalidomide in a patient with bleeding portal hypertensive enteropathy.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Compassionate Use Trials; Female; Gastrointestinal Hemorrha | 2010 |
[The mechanisms of thalidomide in treatment of angiodysplasia due to hypoxia].
Topics: Angiodysplasia; Cell Hypoxia; Cells, Cultured; Endothelial Cells; Humans; Hypoxia-Inducible Factor 1 | 2009 |
Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide.
Topics: Angiodysplasia; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Thalidomide; von Willebran | 2009 |
[Thalidomide therapy for gastrointestinal angiodysplasia].
Topics: Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; R | 2009 |
Somatostatin analogues for bleeding gastrointestinal angiodysplasias: when should thalidomide be prescribed?
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Human | 2011 |
[Thalidomide for recurrent gastrointestinal bleeding caused by angiodysplasia: report of one case].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Intestines; Male | 2011 |
Role of vascular endothelial growth factor in angiodysplasia: an interventional study with thalidomide.
Topics: Adult; Aged; Angiodysplasia; Angiogenesis Inhibitors; Cell Proliferation; Cells, Cultured; Dose-Resp | 2012 |
Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Diseases; Gastrointestinal H | 2011 |
Successful treatment with thalidomide for a patient with recurrent gastrointestinal bleeding due to angiodysplasia diagnosed by capsule endoscopy.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Female; Gastrointestinal Hemorrhag | 2013 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Thalidomide for the treatment of bleeding angiodysplasias.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Tha | 2003 |
Von Willebrand's disease and angiodysplasia treated with thalidomide.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Humans; Male; Middle Aged; Thalidomide; Treatment Outcome; | 2006 |
Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Angiography; Blood Transfusion; Capsule Endoscopy; Child; C | 2006 |
[Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias].
Topics: Aged, 80 and over; Anemia, Iron-Deficiency; Angiodysplasia; Angiogenesis Inhibitors; Blood Transfusi | 2006 |
Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Disease Progres | 2006 |
Thalidomide. Treat with caution!
Topics: Adult; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Cachexia; Drug Design; Female; Hu | 2006 |
Thalidomide as treatment for digestive tract angiodysplasias.
Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; L | 2006 |
A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Pi | 2008 |